Casana raises $ 30 million for effortless home health monitoring –

0
94


Casana raises $ 14 million for home heart health monitoring device

What you should know:

Casana, a health technology The company that is reinventing home health control announced that it has raised $ 30 million in Series B funding, bringing the total capital raised to $ 46 million led by Morningside with the participation of Matrix Partners, as well as Series A investors general catalyst i Fund for outsiders.

– Series B funding will allow Casana to expedite the presentation of the Heart Seat by the FDA with the goal of obtaining FDA approval and bringing this important new device to patients in 2022.


New home health control effortlessly

Home health monitoring, better known as remote patient monitoring (RPM), has grown in importance due to the advent of COVID-19, as well as the subsequent need for continuous out-of-home monitoring solutions. ‘clinical environment. The global RPM market grew in value in 2020 to $ 23.2 billion and is expected to grow fivefold by 2025. The remote patient monitoring market in North America is only expected to exceed 72,800. million dollars in 2025, according to one report published by MarketsandMarkets. The biggest challenge for most home health monitoring devices is patient compliance.

Founded in 2018 by Dr. Nicholas Conn, Casana’s mission is to assist medical teams in the care management of patients with chronic conditions beyond the four walls of the hospital, starting with more than 6 million people in the United States. living with heart failure. Casana is unlocking a new category in healthcare technologies that allow for effortless, integrated and consistent monitoring of heart health at home. Casana will use its Series B funding to accelerate the development and commercialization of the company’s first product, The Heart Seat, an IoT heart health toilet seat that captures clinically relevant measures such as heart rate, blood pressure arterial, blood oxygenation, and cardiac output.

The heart seat

The Heart Seat Cas that Casana is marketing was originally developed by founder Nicholas Conn, Ph.D. at the Rochester Institute of Technology, to enable physicians to understand the health of their patients between physician visits, without adding burden to their workflow. The Heart Seat ™ is a self-contained, cloud-based cardiovascular control system based on the toilet seat, which measures important health parameters to assess heart health.

Heart Seat has already been tested through multiple peer-reviewed research studies and is currently seeking FDA approval. By using The Heart Seat’s passive and consistent home cardiac monitoring data, physicians will have a better understanding of chronic conditions and will be able to address the patient’s needs as they come out.



Source link